

Validation of mild cognitive impairment in Parkinson's disease

<https://www.neurodegenerationresearch.eu/survey/validation-of-mild-cognitive-impairment-in-parkinsons-disease/>

Principal Investigators

dr. G.J. Geurtsen

Institution

AMC

Contact information of lead PI

Country

Netherlands

Title of project or programme

Validation of mild cognitive impairment in Parkinson's disease

Source of funding information

Parkinson Vereniging

Total sum awarded (Euro)

€ 68,338

Start date of award

01/01/2014

Total duration of award in years

2

Keywords

Research Abstract

This project aims to validate the MDS PD-MCI criteria by pooling and analyzing cross-sectional and longitudinal neuropsychological databases comprising 5,500 PD patients and 1,700 controls. After applying the MDS PD-MCI Level I and Level II criteria, rates of conversion to PD-dementia and predictive variables for conversion to PD-dementia will be established. This study will also assist in identifying whether revisions of the PD-MCI criteria are required. Goals 1. Validation of the MDS PD-MCI criteria comparison of the two levels of criteria (abbreviated assessment {I} versus comprehensive assessment {II}) in their ability to detect PD-MCI and predict conversion to dementia applicability of the criteria. 2. Definition of best cut-off score to discriminate patient with and without PD-MCI to predict conversion to dementia

3. Generating epidemiologic data by:

defining the prevalence of PD-MCI
comparing the prevalence across different sites/cohort types
defining the prevalence of the different subtypes of PD-MCI

4. Determine relationship PD-MCI, mood and Quality of Life analyzing mood and Quality of Life in no-PD-MCI, PD-MCI and PDD groups

Additional Information

The 24 international sites have PD cohorts that are being combined. These cohorts include 3,600 PD patients and 1,500 controls to validate level I in 2,100 patients whom 82% participate in longitudinal studies and 1,500 patients to validate level II. Just over 640 (43%) of those level II patients are followed longitudinally. Two PhD student have started October 2013 and the planned duration of the validation project is two years.

Further information available at:

<http://www.movementdisorders.org/MDS/About/Committees--Other-Groups/Study-Groups/Validation-of-Mild-Cognitive-Impairment-in-Parkinson-Disease-MCI-Study-Group.htm>

Types:

Investments < €500k

Member States:

Netherlands

Diseases:

N/A

Years:

2016

Database Categories:

N/A

Database Tags:

N/A